// App-Quantinova.ai

THU0189 : EFFICACY AND SAFETY OF NINTEDANIB IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASE TREATED WITH DMARDS AND/OR GLUCOCORTICOIDS AT BASELINE

Researchers

Presenter

  • M. Aringer

Principal Investigators

  • J. Pope

  • C. Kelly

  • A. M. Hoffmann-Vold

  • J. Belperio

  • A. James

  • C. Coeck

  • M. Quaresma

  • E. Matteson

Medical Centers

  • Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany

  • Division of Rheumatology, University of Western Ontario, Schulich School of Medicine, London, Ontario, Canada

  • Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom

  • Department of Oncology, Oslo University Hospital, Oslo, Norway

  • David Geffen School of Medicine at UCLA, Los Angeles, California, United States

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • SCS Boehringer Ingelheim Comm. V., Brussels, Belgium

  • Mayo Clinic College of Medicine and Science, Urology, Rochester, United States of America

Locations

  • Germany

  • Canada

  • United Kingdom

  • Norway

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Interstitial lung disease

Biomarkers

  • N/A

Drug/Treatment

  • Glucocorticoid

  • Nintedanib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved